Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Remuneration Information 2019

Nov 26, 2019

5262_rns_2019-11-26_fa118e78-4e2b-4a2f-9f79-f2bba262c564.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7382U

GlaxoSmithKline PLC

26 November 2019

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 26 November 2019

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan
Period of return: From: 1 May 2019 To: 31 October 2019
Balance of unallotted securities under scheme(s) from previous return: 153,724
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 153,724
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 26 November 2019

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares
Period of return: From: 1 May 2019 To: 31 October 2019
Balance of unallotted securities under scheme(s) from previous return: 1,265,008
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 429,913
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 835,095
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 26 November 2019

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline 2009 Share Option Plan - ADS
Period of return: From: 1 May 2019 To: 31 October 2019
Balance of unallotted securities under scheme(s) from previous return: 5,911,296
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 519,880
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 5,391,416
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 26 November 2019

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline plc Share Save Plan 2012
Period of return: From: 1 May 2019 To: 31 October 2019
Balance of unallotted securities under scheme(s) from previous return: 2,326,896
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 181,084
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 2,145,812
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLRKMMZMDVFGLZM